ALK-rearrangements and testing methods in non-small cell lung cancer: a review.

摘要: The anaplastic lymphoma tyrosine kinase (ALK) gene was first described as a driver mutation in non-Hodgkin's lymphoma. Dysregulated ALK expression is now an identified nearly twenty different human malignancies, including 4-9% of non-small cell lung cancers (NSCLC). inhibitor crizotinib more effective than standard chemotherapeutic agents treating positive NSCLC, making molecular diagnostic testing for dysregulated necessary step identifying optimal treatment modalities. Here we review ALKmediated signal transduction pathways and compare the protocols used to identify NSCLC. We also discuss use second generation inhibitors known mechanisms resistance